US FDA approves two biosimilars for blockbuster eye drug Eylea
Adds background in paragraphs 2-4
May 20 (Reuters) -The U.S. Food and Drug Administration (FDA)on Monday approved two close copies of Regeneron Pharmaceuticals' REGN.O Eylea, its first-ever clearance to biosimilar versions of the blockbuster eye treatment.
The agency approved Biocon Biologics' Yesafili as well as Samsung Bioepis and Biogen's BIIB.O Opuviz, while also allowing interchangeability, or the drug's substitution with biosimilars without the need for a doctor's advice.
It was not immediately clear when the therapies would be launched. Regeneron has filed lawsuits against companies such as Amgen AMGN.O and Biocon, which are seeking to bring Eylea biosimilars to the U.S. market.
Regeneron recorded U.S. sales of $5.72 billion from its regular 2 milligram (mg) doseof Eylea last year, but the drug faces pressurefrom rivals including Roche's ROG.S Vabysmo as well as a looming biosimilar threat.
Regeneron had flagged in its 2023 annual report that it might lose market exclusivity for Eylea on May 17 this year.
To counter those challenges, Regeneron has been focusing on Eylea's higher 8 mg dose, which recorded sales of $200 million in the first quarter.
Biocon Biologics is a unit of Indian drugmaker Biocon BION.NS, while Samsung Bioepis is owned by Samsung Biologics 207940.KS.
Regeneron, Samsung Bioepis, Biocon and Biogen did not immediately respond to Reuters' requests for comment.
Reporting by Leroy Leo and Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar and Anil D'Silva
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
